Searched for
NEW ANTIBIOTIC CANDIDATE
CG Power's growth momentum strong, but valuation comfort missing: Sandip SabharwalCG Power expands its switchgear production, signaling strong demand in the power equipment sector. However, market expert Sandip Sabharwal ...- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- Wockhardt raises Rs 480 crore to pare debt, fund drug trialWockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of gl...
- Can Kerala's antibiotic abuse project inspire India's antimicrobial resistance fight?In 2019, nearly 300,000 deaths in India were due to AMR. Over 1 million deaths were linked to drug resistance, making infections more chall...
- Researchers develop new class of antibiotics to fight drug-resistant bacteriaResearchers have developed a promising class of antibiotics targeting Carbapenem-resistant Acinetobacter baumannii (CRAB), a bacterium resi...
- Wockhardt initiates phase-III clinical study of new antibiotic candidateWCK 5222 is a drug, which is entirely a new class of antibiotic known as "β-lactam ENHANCER", and is targeted for treatment of hospitalised...
- Drug discovery gaps can only be filled by returning to the root of medicine, says this scientistNatural products from microbes and plants are the biggest resource for drug discovery.
- Bill Clinton in hospital for non-COVID-related infectionClinton, 75, was admitted to the University of California Irvine Medical Center on Tuesday evening for a non-COVID-related infection, Angel...
- 20 CPSEs, units in pipeline for strategic sale: MoS for Finance Anurag Singh ThakurThe CPSEs which are under consideration for closure/ under litigation are Hindustan Fluorocarbon Ltd (HFL), Scooters India, Bharat Pumps & ...
- Bugworks Research set for pre-clinical drug trialsCARB-X was formed two years ago as a public-private partnership to tackle the rising menace of antibiotic resistance.
- This type of onion can help fight drug-resistant tuberculosisWhen a patient has a bacterial TB infection, they may be prescribed an antibiotic.
- Now smaller firms developing antibiotics but will society, politicians accept high prices?As a woman dies in the US from a superbug infection likely caught in India, four domestic companies are taking up the cudgels in the area o...
- Hillary Clinton 'fit to serve' as US president: Doctor"She is in excellent mental condition," said her physician, four days after the Democratic nominee nearly collapsed during the 15th anniver...
- Superbugs and subsidies draw big pharma back to antibioticsBig Pharma is creeping back into development of new antibiotics after decades of largely ignoring the business due to the scant rewards off...
- Sun Pharma bids to acquire InSite Vision IncSources close to the transaction have indicated that Sun Pharma has already bid for US OTC Market listed Insite Vision for Rs 300 cr.
- Common antacid may treat tuberculosis: StudyTuberculosis continues to be a global pandemic, second only to AIDS as the greatest single-agent killer in the world.
- New compound may treat HIV, drug-resistant TBResearchers, including one of Indian-origin, have developed a new molecule that may treat multi-drug resistant tuberculosis and even HIV in...
- Drug combo speeds up TB treatmentThe drug combination, known as PaMZ, killed more bacteria than standard treatment and was effective in treating drug-resistant tuberculosis.
- Nicholas Piramal may offer research arm stake to PEsMumbai-based drug major Nicholas Piramal India (NPIL) is in talks with private equity funds for the sale of a ‘small’ stake in its research...
- Nicholas Piramal gets FDA okay for cancer drug trialsNicholas Piramal announced on Monday that it had received approval from the USFDA to start clinical trials on humans for its new cancer dru...
Load More
